Terumo Health Outcomes, in alliance with Medis Medical Imaging, has unveiled a strategic collaboration focused on advancing cardiovascular care across the United States. The initiative aims to integrate Terumo’s innovative ePRISM clinical decision support system alongside Medis’ QFR technology, a non-invasive software tool that evaluates coronary artery physiology from angiography. The deployment of these cutting-edge tools will initially occur at select clinical sites, utilizing up-to-the-minute data from electronic health records to create forward-thinking insights.
The ePRISM platform assists doctors in evaluating patient risk while fine-tuning treatment approaches, and Medis’ QFR solution has evidenced a notable 34% decrease in serious cardiac events post-interventional procedures during a clinical study.
“This partnership highlights Terumo’s dedication to crafting a pioneering medical care infrastructure that not only seeks to boost clinical outcomes but also enhances the overall treatment process,” stated Ryan Graver, Senior Divisional Vice President at Terumo Health Outcomes. “By merging our ePRISM system with Medis’ QFR technology and TIS devices, we’re providing medical professionals with an integrated toolkit that improves both procedural effectiveness and patient results.”
The collaboration signifies a pivotal advancement in strengthening clinical decision support resources and streamlining healthcare operations. It is anticipated that this partnership will significantly enhance patient results through detailed anatomical and physiological review of coronary artery disease (CAD).
The PIONEER IV study, involving 2,540 participants, intends to assess the combined use of ePRISM and QFR.
“We are excited to collaborate with Terumo Health Outcomes to explore new frontiers in cardiovascular imaging and decision support,” said Maya Barley, CEO of Medis. “This union presents a robust solution that amplifies both diagnostic precision and therapeutic planning, reiterating our commitment to advancing patient care via innovation and global partnerships.”